Alkermes

ALKSApproved

Dublin, IrelandFounded 1987alkermes.com

Alkermes is a neuroscience-focused biopharmaceutical company dedicated to making a meaningful difference for patients with complex and stigmatized conditions. The company's strategy integrates patient-inspired science, advanced development capabilities, and a commercial portfolio, including the recently acquired once-nightly sodium oxybate for narcolepsy. With a strong leadership team and a values-driven culture recognized as an employer of choice, Alkermes is advancing a pipeline of novel candidates, most notably the orexin 2 receptor agonist alixorexton, poised to enter Phase 3 trials for sleep disorders in 2026.

Market Cap

$4.7B

Founded

1987

Focus

Small Molecules

ALKS · Stock Price

USD 28.15+0.72 (+2.62%)

Historical price data

AI Company Overview

Technology Platform

Deep neuroscience expertise applied through an integrated research and development strategy, with capabilities in drug delivery, formulation, clinical development, and commercialization for central nervous system disorders.

Pipeline Snapshot

92 drugs in pipeline, 35 in Phase 3

Drug	Indication	Stage
XR-NTX 380 mg, intramuscular injection + Placebo intramuscular injection	Alcohol Use Disorder	Approved
Naltrexone for extended-release injectable suspension + Oral naltrexone	Opioid-Related Disorders	Approved
Aripiprazole Lauroxil	Schizophrenia	Approved
Naltrexone	Opioid-Related Disorders	Approved
Extended release injectable naltrexone (Vivitrol)	Alcohol Dependence	Approved

Funding History

Total raised: $798M

Debt$450MUndisclosedNov 15, 2017

Debt$300MUndisclosedMar 15, 2015

IPO$48MUndisclosedJun 27, 1991

FDA Approved Drugs

LYBALVINDAMay 28, 2021

ARISTADA INITIO KITNDAJun 29, 2018

ARISTADANDAOct 5, 2015

Opportunities

Major growth opportunities include the potential approval and launch of alixorexton, a novel orexin agonist for narcolepsy and idiopathic hypersomnia, representing a first-in-class mechanism.

Expanding the label of Lybalvi into the pediatric population and growing the recently acquired once-nightly sodium oxybate franchise in sleep disorders also present significant near-term commercial opportunities.

Risk Factors

Key risks include clinical trial failure of the pivotal alixorexton program, regulatory setbacks, intense competition in both sleep and psychiatry markets, and the challenge of successfully integrating and commercializing acquired assets.

The company's valuation is highly dependent on the success of its late-stage pipeline.

Competitive Landscape

Alkermes faces competition from established players like Jazz Pharmaceuticals in sleep disorders and numerous large pharma/biotech companies in schizophrenia/bipolar disorder. Its differentiation lies in its pure-play neuroscience focus, integrated capabilities, and novel mechanisms like the orexin 2 receptor agonist alixorexton, which could offer a superior therapeutic profile if successful.

Publications

Patents

Pipeline

FDA Approvals